Results 141 to 150 of about 1,439 (152)

Ceftaroline fosamil as first-line versus second-line treatment for acute bacterial skin and skin structure infections (ABSSSI) or community-acquired bacterial pneumonia (CABP)

Journal of Chemotherapy, 2016
David J Guervil, Ali Hassoun
exaly  

Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials.

Open Forum Infectious Diseases, 2017
G Ralph Corey
exaly  

Factors Driving Emergency Department Revisits or Hospitalization Within 30 Days Post-Discharge (DC) in Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Open Forum Infectious Diseases, 2015
Edward Stenehjem, Jack Brown
exaly  

456. Dalbavancin, a Long-Acting Lipoglycopeptide Antimicrobial Agent, Reduces Length of Stay and Improves Patient Work Productivity in a Hospital Critical Pathway for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)—the ENHANCE ABSSSI Trial

Open Forum Infectious Diseases, 2019
Matthew W McCarthy, Justin J Choi
exaly  

Evaluation of Health-Related Quality of Life (HRQL) in ABSSSI Patients After Antibiotic Discontinuation in a Phase 3 Trial

Open Forum Infectious Diseases, 2015
Kalpana Gupta
exaly  

266Dalbavancin vs Vancomycin for the treatment of acute bacterial skin and skin structure infections (ABSSSI): a subanalysis from the DISCOVER studies

Open Forum Infectious Diseases, 2014
Michael Dunne, Mark H. Wilcox, Sailaja Puttagunta   +2 more
exaly  

All-Cause Readmission Following Treatment With Linezolid for MRSA-ABSSSI: A Propensity Score Analysis

Open Forum Infectious Diseases, 2015
Susan L Davis, Emily T Martin, Paul Lephart   +2 more
exaly  

Use of lipoglycopeptides for moderate to severe ABSSSI in the emergency department

American Journal of Emergency Medicine
Cierra N Treu
exaly  

Comparison of Digital Planimetry and Ruler Technique To Measure ABSSSI Lesion Sizes in the ESTABLISH–1 Study

Surgical Infections, 2014
Carisa De Anda, Philippe Prokocimer
exaly  

Comparison of Dalbavancin, Oritavancin and Vancomycin Pharmacodynamics Using Clinical Targets Against ABSSSI Pathogens

Open Forum Infectious Diseases, 2016
exaly